A curated stream of high-signal insights across Technology, Healthcare, Lifesciences, AI, Oncology, Business, Entrepreneurship, Leadership, Philosophy and beyond.
Thoughtful, cross-disciplinary content designed to expand how you think, not just what you know.
No noise. Only substance.
Consolidation dominates the conversation in Indian eye care. The numbers tell a different story.
The organised sector still accounts for only 14–16% of market value. The overwhelming majority of care continues to be delivered by independent, standalone practices. Most individual ophthalmologists will never receive a serious acquisition offer.
Everyone watches HAL and the big shipyards land the headline contracts.
But the quiet winners are the Tier-2 subsystem suppliers — the ones building radars, avionics, and electronics.
India is the “Pharmacy of the World”— not by accident, but by design.
The 1970 Patents Act flipped the script: instead of product patents (owning the molecule), India allowed process patents. Any company could legally manufacture the same drug using a different method — making patented medicines up to 99% cheaper.
BCG (2026)
Most companies don’t die from external shocks — they rot from the inside.
India never lacked desire — it lacked liquidity and timing.
Instead of waiting for incomes to rise, Indian companies mastered three ways to hide the gap between what people want and what they can afford:
Every year founders chase the “IRL connection economy” — market of businesses that create and monetize real-world, offline connections and experiences (think premium clubs, event platforms, fitness communities) - a supposed $400B market.
Most fail.
Urgency often looks like leadership — frantic reactions, constant escalations, visible busyness.
But it usually creates noise, disrupts teams, and ignores root causes.
